Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0107225
DC FieldValue
dc.titleEvaluating the cost-effectiveness of lifestyle modification versus metformin therapy for the prevention of diabetes in Singapore
dc.contributor.authorPng M.E.
dc.contributor.authorYoong J.S.-Y.
dc.date.accessioned2019-11-07T05:08:39Z
dc.date.available2019-11-07T05:08:39Z
dc.date.issued2014
dc.identifier.citationPng M.E., Yoong J.S.-Y. (2014). Evaluating the cost-effectiveness of lifestyle modification versus metformin therapy for the prevention of diabetes in Singapore. PLoS ONE 9 (9) : e107225. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0107225
dc.identifier.issn19326203
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/161778
dc.description.abstractBackground: In Singapore, as diabetes is an increasingly important public health issue, the cost-effectiveness of pursuing lifestyle modification programs and/or alternative prevention strategies is of critical importance for policymakers. While the US Diabetes Prevention Program (DPP) compared weight loss through lifestyle modification with oral treatment of diabetes drug metformin to prevent/delay the onset of type 2 diabetes in pre-diabetic subjects, no data on either the actual or potential cost effectiveness of such a program is available for East or South-east Asian populations. This study estimates the 3-year cost-effectiveness of lifestyle modification and metformin among pre-diabetic subjects from a Singapore health system and societal perspective. Methodology: Cost effectiveness was analysed from 2010-2012 using a decision-based model to estimate the rates of getting diabetes, healthcare costs and health-related quality of life. Cost per quality-Adjusted life year (QALY) was estimated using costs relevant to the time horizon of the study from Singapore. All costs are expressed in 2012 US dollars. Principal Findings: The total economic cost for non-diabetic subjects from the societal perspective was US25,867, US28,108 and US26,177 for placebo, lifestyle modification and metformin intervention respectively. For diabetic patients, the total economic cost from the societal perspective was US32,921, US35,163 and US33,232 for placebo, lifestyle modification and metformin intervention respectively. Lifestyle modification relative to placebo is likely to be associated with an incremental cost per QALY gained at US36,663 while that of metformin intervention is likely to be US6,367 from a societal perspective. Conclusion: Based on adaptation of the DPP data to local conditions, both lifestyle modification and metformin intervention are likely to be cost-effective and worth implementing in Singapore to prevent or delay the onset of type 2 diabetes. However, the cost of lifestyle modification from the societal perspective would have to be reduced in order to match the cost-effectiveness of metformin intervention. © 2014 Png, Yoong. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20191101
dc.subjectmetformin
dc.subjectantidiabetic agent
dc.subjectmetformin
dc.subjectArticle
dc.subjectclinical evaluation
dc.subjectcontrolled study
dc.subjectcost effectiveness analysis
dc.subjectdiabetes mellitus
dc.subjectdisease association
dc.subjectdrug cost
dc.subjectdrug efficacy
dc.subjecthuman
dc.subjectlifestyle modification
dc.subjectmajor clinical study
dc.subjectquality adjusted life year
dc.subjectSingapore
dc.subjecttreatment outcome
dc.subjecttreatment planning
dc.subjectbehavior therapy
dc.subjectcost benefit analysis
dc.subjectDiabetes Mellitus, Type 2
dc.subjecteconomics
dc.subjecthealth care cost
dc.subjectimpaired glucose tolerance
dc.subjectlifestyle
dc.subjectprocedures
dc.subjectquality of life
dc.subjectBehavior Therapy
dc.subjectCost-Benefit Analysis
dc.subjectDiabetes Mellitus, Type 2
dc.subjectHealth Care Costs
dc.subjectHumans
dc.subjectHypoglycemic Agents
dc.subjectLife Style
dc.subjectMetformin
dc.subjectPrediabetic State
dc.subjectQuality of Life
dc.subjectQuality-Adjusted Life Years
dc.subjectSingapore
dc.typeArticle
dc.contributor.departmentSAW SWEE HOCK SCHOOL OF PUBLIC HEALTH
dc.description.doi10.1371/journal.pone.0107225
dc.description.sourcetitlePLoS ONE
dc.description.volume9
dc.description.issue9
dc.description.pagee107225
dc.published.statePublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pone_0107225.pdf293.42 kBAdobe PDF

OPEN

PublishedView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons